CVS plans to create two publicly traded companies by separating retail pharmacy operations from health solutions.
Why it matters: The proposed split could affect debt allocation, contracts between the two companies, pharmacy-benefit-manager economics and regulatory scrutiny. Investors and operators will need to assess whether the separated businesses can preserve the benefits of their current links.
- CVS expects to complete the separation in the first half of 2028.
- The retail pharmacy and community healthcare company would include approximately 9,000 pharmacies, mail pharmacy, MinuteClinic, virtual care and Health100.
- Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health would remain in the healthcare-solutions company.
- CVS shares fell 12.5% to $79.96 on November 4, cutting nearly $15 billion from the company's market value.
CVS Health announced an intent on November 4, 2026, to create two independent, publicly traded companies. The company expects the separation in the first half of 2028. It remains an announced intention, not a completed transaction: CVS said it is subject to board approval, an effective Form 10 registration statement and tax-related confirmation.
One company would contain Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health. The other would be the retail pharmacy and community healthcare business, including approximately 9,000 pharmacies, mail pharmacy, MinuteClinic, virtual care and Health100. David Joyner is expected to lead the healthcare-solutions company, while Prem Shah is expected to lead the retail pharmacy and community healthcare company.
The plan would unwind part of CVS's 2018 strategy. CVS completed its approximately $78 billion acquisition of Aetna that year. The 2018 annual report says CVS financed part of the cash consideration with approximately $45 billion of new debt. The materials provided do not establish whether the $78 billion acquisition figure includes assumed debt.
The split would not fully dismantle CVS's vertical integration because Aetna, Caremark, specialty pharmacy and care-delivery businesses would remain together. CVS has not disclosed how it would allocate debt, corporate costs, technology, employees, contracts or shared services, or how the two companies would transact after separation.
CVS reported third-quarter adjusted earnings of $2.09 per share, while the $1.65 figure was the analyst consensus cited in a Reuters report carried by Investing.com. The report also said shares fell 12.5% to $79.96 on November 4, reducing CVS's market value by nearly $15 billion.
By the numbers
- $78 billion - approximate value of CVS's 2018 Aetna acquisition; the provided materials do not say whether it includes assumed debt.
- $45 billion - approximate new debt used to finance part of the Aetna acquisition's cash consideration, according to CVS's 2018 annual report.
- 9,000 - approximate number of pharmacies planned for the retail pharmacy and community healthcare company.
Yes, but: CVS has not disclosed the proposed debt allocation, intercompany contracts, shared-service arrangements or other separation terms. The plan also remains subject to board approval and regulatory and filing-related steps.
What's next: CVS expects the separation in the first half of 2028. Before then, it must obtain board approval, make an effective Form 10 registration statement and receive tax-related confirmation.